Organization (Academic)
University of the Incarnate Word
ClinicalTrials.gov lists University of the Incarnate Word as lead sponsor of 15 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of the Incarnate Word: 15 lead-sponsored trials and 1 legal-entity registration.
Disease areas (11)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Meibomian Gland Dysfunction | 5 |
| Dry Eye Syndromes | 3 |
| Glaucoma | 3 |
| Glaucoma, Open-Angle | 2 |
| Color Vision Defects | 1 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2015 | 1 |
| 2014 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Dorzolamide Hcl 2% Oph Soln | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=8) | 57% on time (n=7) |
Journals published in (60)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Investigative ophthalmology & visual science | 6 |
| Nutrients | 4 |
| Clinical & experimental optometry | 3 |
| Optometry and vision science : official publication of the American Academy of Optometry | 3 |
| Digestive diseases and sciences | 2 |
Showing 5 of 60 journals.
Financing and grant events (22)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-05 | NIH grant | 119,498 | Reporter |
| 2025-07-15 | NIH grant | 166,711 | Reporter |
| 2025-04-11 | NIH grant | 29,811 | Reporter |
| 2024-09-16 | NIH grant | 166,711 | Reporter |
| 2024-07-31 | NIH grant | 119,498 | Reporter |
Showing 5 of 22 events.
Latest dated events (39)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-09-05 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-15 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-04-11 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-09-16 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-07-31 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 39 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| UNIVERSITY OF THE INCARNATE WORD | Certificate of waiver | Active |
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| PRIMA1 | Trial sponsor | Named in trial inclusion criteria |
| PRIMA1 | Trial sponsor | Mentioned in trial text |
Biomarkers this organization publishes on (17)
Shown in this order: most publications first.
Showing 5 of 17 biomarkers.
On Scientist.com
University of the Incarnate Word is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.
Work with University of Incarnate Word Feik School of Pharmacy on Scientist.com
For prices, more details, or to contact University of Incarnate Word Feik School of Pharmacy, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.